Erythropoietins should be used according to guidelines.
Aapro
Matti S
MS
Birgegård
Gunnar
G
Bokemeyer
Carsten
C
Cornes
Paul
P
Foubert
Jan
J
Gascon
Pere
P
Glaspy
John
J
Hellström-Lindberg
Eva
E
Link
Hartmut
H
Ludwig
Heinz
H
Osterborg
Anders
A
Repetto
Lazzaro
L
Soubeyran
Pierre
P
D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017277:Drug Approval; D004348:Drug Labeling; D004921:Erythropoietin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D019983:Guideline Adherence; D006397:Hematinics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D006397:Hematinics; D004921:Erythropoietin